Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme

Abstract Background In recent years, PD-1/PD-L1 immune checkpoint inhibitors have improved cancer therapy in many tumor types, but no benefit of immune checkpoint therapy has been found in glioblastoma multiforme (GBM). Based on the results of our earlier work, which showed a reduction of PD-L1 expr...

Full description

Bibliographic Details
Main Authors: Sabrina Heynckes, Karam Daka, Pamela Franco, Annette Gaebelein, Jan Hendrik Frenking, Roberto Doria-Medina, Irina Mader, Daniel Delev, Oliver Schnell, Dieter Henrik Heiland
Format: Article
Language:English
Published: BMC 2019-02-01
Series:BMC Cancer
Subjects:
Temozolomide
Recurrent GBM
PD-L1 immunotherapy
Online Access:http://link.springer.com/article/10.1186/s12885-019-5308-y

Internet

http://link.springer.com/article/10.1186/s12885-019-5308-y

Similar Items